Klothos Neurosciences Inc.

Company Overview

Business Model: Klotho Neurosciences, Inc., formerly known as ANEW Medical, Inc., is a biopharmaceutical company focused on developing essential medicines for chronic diseases, including cancer, cardiovascular, and neurodegenerative disorders. The Company operates through two primary licensed platforms: a generic drug portfolio and a biosimilar biologics platform for cancer treatment, and a proprietary, patented gene therapy platform. The gene therapy platform utilizes a gene therapy approach to introduce a therapeutic protein called "Klotho" into the body to treat neurodegenerative diseases. The Company acquired five market-approved anti-cancer drugs for sale in Germany on September 12, 2022, and two off-patent bio generic antibodies from Reliance Life Sciences on November 27, 2014. Its gene therapy product candidates are currently in the pre-clinical stage of development.

Market Position: Klotho Neurosciences, Inc.'s primary strategic focus is the advancement of a sustainable portfolio of cell and gene therapy product candidates for age-associated neurologic diseases, encompassing both rare "orphan diseases" and larger patient populations. The Company claims no direct competition in Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease (AD), Parkinson’s disease (PD), or other neurodegenerative disorders involving the human secreted-Klotho (s-KL) gene or s-KL protein. However, it faces significant competition in the biosimilar biologics market from established biotechnology and pharmaceutical companies, including those with approved biosimilar versions of bevacizumab and rituximab already on the market. In the broader Alzheimer's gene therapy space, competitors include University of California San Diego School of Medicine (BDNF gene therapy) and Unity Biotechnology (Klotho product candidate in "lead optimization"). For ALS, competitors include Biogen, Eikonoklastes Therapeutics, and Neurosense Therapeutics, though Amylyx's Relyvrio was recently removed from the market due to lack of efficacy.

Recent Strategic Developments:

• Name Change: Effective July 24, 2024, the Company changed its legal name from ANEW Medical, Inc. to Klotho Neurosciences, Inc. to better reflect the strategic focus on its proprietary products.
• Business Combination: On June 21, 2024, Klotho Neurosciences, Inc. (then Redwoods Acquisition Corp.) completed a Business Combination with ANEW Medical, Inc. (Wyoming), which became a wholly-owned subsidiary. For accounting purposes, this was treated as a reverse acquisition, with ANEW Medical, Inc. (Wyoming) as the accounting acquirer.
• Capital Structure Post-Merger: In connection with the merger, the Company issued 6,000,000 shares for ANEW Medical, Inc., valuing it at $60 million ($10 per share). Immediately after the Business Combination, 15,130,393 shares of Common Stock were outstanding, with 2,875,000 shares held in escrow for the Redwoods founders. Additionally, 12,030,000 warrants were immediately exercisable (11,500,000 public warrants and 530,000 private warrants).
• PIPE Financings:
  • Redwoods PIPE Financing: Raised $2,000,000 from accredited investors for 750,000 shares. Approximately $1,768,661 was used to settle transaction costs, with $181,339 in net cash proceeds received. The note was converted into shares and fully settled by December 31, 2024.
  • ANEW PIPE Financing: Raised $2,000,000 from accredited investors for 854,257 units. $1,000,000 was used to settle transaction costs, with $950,000 in cash proceeds received. The note was converted into shares and fully settled by December 31, 2024.
• Contingent Consideration: Certain ANEW Medical, Inc. stockholders may receive up to an additional 2,000,000 shares of Common Stock based on stock price targets ($15.00 within three years and $20.00 within five years post-closing). On November 6, 2024, the Board modified the Business Combination Agreement, releasing 2,976,948 contingent shares to pre-closing ANEW Medical, Inc. stockholders due to dilution.
• Assumed Liabilities: Klotho Neurosciences, Inc. assumed $589,081 in cash and $568,111 in income tax payable from Redwoods, with the income tax payable settled in full by December 31, 2024.
• Proposed Acquisition: On March 26, 2025, the Company entered into a Share Exchange Agreement to acquire SB Security Holdings, LLC, an internet-connected video doorbell service company, in exchange for 90% of the Company's fully-diluted common stock. This acquisition is subject to customary closing conditions, including stockholder and Nasdaq approval.
• Nasdaq Listing Extension: On March 31, 2025, Nasdaq granted the Company an extension to continue its listing until August 13, 2025, contingent on completing the acquisition of SB Security Holdings, LLC.

Geographic Footprint: Klotho Neurosciences, Inc. maintains three remote offices in Omaha, NE, Charlotte, NC, and Scottsdale, AZ, which are provided rent-free by employees. The Company's gene therapy patents are issued in the U.S., Europe, China, and Hong Kong, with applications pending in Canada and Japan. Its biosimilar license territory covers North America, Europe, and Israel. The Company plans to seek market approval in countries where it holds issued and/or pending patents.

Financial Performance

Revenue Analysis

The Company did not generate any revenue for the years ended December 31, 2024, and December 31, 2023.

Profitability Metrics:

• Gross Margin: 0.0%
• Operating Margin: Not applicable (no revenue)
• Net Margin: Not applicable (no revenue)

Investment in Growth:

• R&D Expenditure: Not explicitly disclosed as a separate line item in the financial statements.
• Capital Expenditures: Not explicitly disclosed.
• Strategic Investments:
  • Licenses and Patents: Total intangible assets were $2,299,554 as of December 31, 2024, up from $2,186,058 in 2023. This includes:
    • Non-Exclusive License Agreement with University of Heidelberg: $179,821 paid as of December 31, 2024.
    • Various Generic Drugs licenses: $736,983.
    • Four Generic Drugs (Encore) licenses: $1,308,270.
    • Needleless Syringe License: $26,060.
    • Patents: $48,420.
  • Sponsored Research Agreement: Two-year budget of 623,100 euros with Universitat Autònoma de Barcelona.

Business Segment Analysis

Klotho Neurosciences, Inc. views its operations and manages its business as one operating and reporting segment, focused on the research and development of essential medicines for chronic diseases.

Product Portfolio:

• Cell and Gene Therapy — α -Klotho gene:
  • Product Candidates: KLTO-101 (AAV9-CMV-sKL) for Alzheimer’s disease and KLTO-202 (AAVmyo-Des-sKL) for Lou Gehrig’s disease (ALS). Both are in pre-clinical development.
  • Development Plans: Plans to complete animal toxicology for KLTO-202 and submit an Investigational New Drug (IND) application to the FDA in 2025 for a first-in-human Phase I "Compassionate Use" study in late-stage ALS patients. Pre-clinical development for KLTO-101 will follow KLTO-202 by six to nine months. The Company plans to seek a corporate partner for KLTO-101.
  • Diagnostic Development: Developing and validating an assay to separate and individually measure Klotho protein isoforms (s-KL, m-KL, p-KL) and metabolites (KL1, KL2) in 2025.
• Generic Drug Portfolio:
  • Product Lines: Five market-approved anti-cancer drugs approved for sale in Germany, acquired on September 12, 2022. These include drugs for the "FOLFOX" and "FOLFIRI" multi-drug regimens used in metastatic colorectal and gastric cancer, and two drugs for metastatic lung cancer.
• Biosimilar Biologics Platform:
  • Product Candidates: Off-patent bio generic antibodies for rituximab (Rituxan ®/MabThera ®), trastuzumab (Herceptin ®), bevacizumab (Avastin ®), and cetuximab (Erbitux ®).
  • Development Status: Initiated preparatory activities for confirmatory Phase 3 clinical trials of bevacizumab-anew and rituximab-anew.

Market Dynamics:

• Gene Therapy: The Company is targeting age-associated neurologic diseases, including Alzheimer's and ALS, based on the potential of the Klotho gene and s-KL protein to counteract cognitive decline, clear beta-amyloid plaques, and offer neuroprotective and myoregenerative properties.
• Biosimilars: The biosimilar market is characterized by price competition, particularly in Europe where prices of innovator products have decreased by 30%-40% or more. In the U.S., acceptance of biosimilar products is improving, leading to decreasing prices for both biosimilar and innovator products.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: None disclosed.
• Dividend Payments: The Company has not declared or paid dividends on its common shares since its formation and does not anticipate paying dividends in the foreseeable future, intending to retain any future earnings for business operations.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: No authorized programs or amounts for future capital returns were disclosed.

Balance Sheet Position:

• Cash and Equivalents: $63,741 as of December 31, 2024, compared to $2,808 as of December 31, 2023.
• Total Debt: $271,753 as of December 31, 2024, compared to $1,467,270 as of December 31, 2023.
• Net Cash Position: $(208,012) as of December 31, 2024, compared to $(1,464,462) as of December 31, 2023.
• Credit Rating: Not disclosed.
• Debt Maturity Profile:
  • Austria Capital LLC Convertible Promissory Note: Principal amount of $1,200,000, issued December 4, 2024, with a maturity date of December 4, 2025. Bears no interest and is convertible into common stock at $0.25 per share after stockholder approval.
  • Red Road Holdings Promissory Note (Q4 2024): $203,324, including guaranteed interest of $21,784.
  • Red Road Holdings Promissory Note (January 2025): $137,715, including guaranteed interest of $14,755, due November 15, 2025.
  • Institutional Investor Senior Convertible Promissory Notes (January 2025): Two notes with an aggregate principal of $2,173,914. Mature on the anniversary of issuance, bear 7% interest, and have an 8% original issuance discount. Convertible into common stock at $0.25 per share.

Cash Flow Generation:

• Operating Cash Flow: $(2,946,512) for the year ended December 31, 2024, compared to $(446,916) for the year ended December 31, 2023.
• Free Cash Flow: Not explicitly calculated, but negative given operating cash flow.
• Cash Conversion Metrics: Not disclosed.

Operational Excellence

Production & Service Model: Klotho Neurosciences, Inc. relies on third-party contract research organizations (CROs) and contract process development and manufacturing organizations (CDMOs) for monitoring and managing manufacturing supply, collecting and managing data for preclinical and clinical programs, and for the execution of preclinical and clinical trials and regulatory submissions.

Supply Chain Architecture: Key Suppliers & Partners:

• API Supplier: Reliance Life Sciences Private Limited (RLS) - exclusive provider of active pharmaceutical ingredients (API) for the Company's biosimilar product candidates (rituximab, trastuzumab, bevacizumab, and cetuximab).
• Research & Development Collaborators:
  • Universitat Autònoma de Barcelona (UAB) and Institució Catalana De Recerca I Estudis Avançats (ICREA) - exclusive license for s-KL gene therapy.
  • Consorcio Centro de Investigación Biomédica en Red (CIBER) and Fundació Hospital Universitari Vall D’hebron — Institut de Recerca (VHIR) - exclusive license for neuronal/neuromuscular diseases.
  • University of Heidelberg, Germany - non-exclusive license for modified AAV capsid polypeptides.
• M&A/Capital Markets Advisory: Chardan Capital Markets.

Facility Network:

• Manufacturing: The Company relies on third-party CDMOs for manufacturing.
• Research & Development: Research activities are conducted in collaboration with UAB scientists, supported by a Sponsored Research Agreement.
• Distribution: The Company currently has no marketing and sales organization and plans to establish one or partner with other companies for commercialization.
• Offices: The Company utilizes three remote offices in Omaha, NE, Charlotte, NC, and Scottsdale, AZ, each approximately 400 sq ft, provided rent-free by employees. The principal executive office is located at 13576 Walnut Street, Suite A, Omaha, NE 68144.

Operational Metrics: No specific operational metrics such as capacity utilization, efficiency measures, or quality indicators were disclosed in the filing.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels: Klotho Neurosciences, Inc. currently has no marketing and sales organization. If its product candidates receive regulatory approval, the Company intends to establish an internal sales and marketing organization with technical expertise and supporting distribution capabilities in major markets where it chooses to retain commercialization rights. Alternatively, the Company may enter into agreements or joint ventures with other pharmaceutical companies to jointly develop and/or commercialize its product candidates, particularly for ex-U.S. markets such as the EU and Japan.

Customer Portfolio: As the Company is in a pre-revenue stage with no approved products for commercial sale, it does not currently have an established customer portfolio or customer concentration metrics.

Geographic Revenue Distribution: Not applicable, as the Company has not generated any revenue.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The Company operates in highly competitive pharmaceutical markets, including the novel gene therapy space and the established biosimilar market. The gene therapy market is characterized by rapid technological change and evolving regulatory landscapes. The biosimilar market, particularly in Europe, has seen significant price competition, while in the U.S., acceptance is growing, leading to decreasing prices for both biosimilar and innovator products. Alzheimer's disease is the most common type of senile dementia, with aging as the primary risk factor. ALS is a devastating neurodegenerative disorder with limited effective treatments.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Alzheimer's Disease (Gene Therapy):
  • University of California San Diego School of Medicine (Phase I clinical trial for brain-derived neurotrophic factor (BDNF) gene therapy).
  • Unity Biotechnology (preclinical Klotho product candidate, likely full-length m-KL or p-KL).
  • Bioviva (mentions Klotho reversing beta-amyloid plaques, no detailed product stage).
• Amyotrophic Lateral Sclerosis (ALS) (Gene Therapy/Other Approaches):
  • Biogen (anti-sense oligonucleotides targeting ataxin-2).
  • Eikonoklastes Therapeutics (Caveolin-1).
  • Neurosense Therapeutics (ciprofloxacin and celecoxib combination).
  • Amylyx (Relyvrio, removed from market due to lack of efficacy).
• Biosimilars (Bevacizumab/Avastin):
  • Amgen Inc. and Allergan (Mvasi).
  • Pfizer Inc. (Zirabev).
• Biosimilars (Rituximab/Rituxan/Mabthera):
  • Pfizer Inc., Mylan Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co. Ltd., Sandoz International GmbH, Reliance Life Sciences, C.H. Boehringer Sohn AG & Co. KG, BioXpress Therapeutics SA, Intas Biopharmaceuticals Ltd. (multiple approved biosimilars already on the market).
• Existing Alzheimer's Drugs: Numerous large pharmaceutical companies, including Allergan, Eisai Co., Ltd., Novartis AG, Pfizer Inc., Eli Lilly and Company, and F. Hoffmann-La Roche Ltd.

Emerging Competitive Threats: The Company faces threats from new entrants, disruptive technologies, and alternative solutions in both the gene therapy and biosimilar markets. Improved versions of reference products or innovator changes to formulations (life cycle extension strategies) could significantly reduce the potential market for the Company's biosimilar product candidates.

Competitive Response Strategy: Klotho Neurosciences, Inc. aims to maintain its competitive advantage by focusing on the advancement of its sustainable portfolio of cell and gene therapy product candidates for age-associated neurologic diseases. The Company is building a platform of next-generation gene and cell delivery technologies (AAV-based, Lentivirus-based, and lipid-based) and integrated internal development capabilities. It also actively explores opportunities to acquire or license new product candidates and form strategic partnerships or collaborations.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Competition: Intense competition from other biotechnology and pharmaceutical companies, many with greater resources and experience, could lead to competitors developing more effective or less expensive therapies, obtaining regulatory approval more rapidly, or blocking the Company's products through patent protection.
• Technology Disruption: Gene therapy is a novel technology, and negative public opinion or increased regulatory scrutiny could adversely impact the development or commercial success of product candidates. There is a potential risk of delayed adverse events following exposure to gene therapy products.
• Product Acceptance: Even if approved, product candidates may fail to achieve market acceptance by physicians, patients, and third-party payors, particularly due to the novelty of gene therapy products.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Supplier Dependency: The Company relies on Reliance Life Sciences for the exclusive supply of API for its biosimilar product candidates.
• Manufacturing & Clinical Trial Reliance: High dependence on contract research organizations (CROs) and contract process development and manufacturing organizations (CDMOs) for manufacturing, quality control, and clinical trials. Failure of these third parties to comply with regulations or meet supply demands could cause significant delays or halt development.
• Gene Therapy Development: The new gene transfer technology for gene therapy product candidates makes predicting development time and cost difficult, with potential for problems or delays in developing reproducible and scalable manufacturing processes.

Financial & Regulatory Risks

Market & Financial Risks:

• Funding Requirements: The Company has incurred significant losses and negative cash flows since inception and will require substantial additional funding to meet financial obligations and pursue business objectives. Current cash is insufficient to complete all necessary development and commercialization activities.
• Regulatory Approval Uncertainty: The regulatory approval processes by the FDA, EMA, and comparable foreign authorities are lengthy, rigorous, and inherently unpredictable. There is no guarantee that any product candidate will receive regulatory approval or be successfully commercialized.
• Reimbursement Uncertainty: Significant uncertainty exists regarding coverage and adequate reimbursement from third-party payors for any approved products, which could limit marketability and revenue generation.
• Product Liability: The use of product candidates could be associated with undesirable side effects or adverse events, leading to product liability claims, substantial liabilities, and potential limitations on commercialization.
• Intellectual Property Infringement: Risk of infringing third-party intellectual property rights, leading to lawsuits, substantial expenses, delays, or inability to commercialize products.
• Patent Protection: Inability to obtain and maintain effective patent rights for product candidates, or challenges to the validity, enforceability, or scope of existing patents, could harm the Company's competitive position.
• Nasdaq Delisting: The Company has failed to meet Nasdaq's minimum market value of publicly held shares, minimum market value of listed securities, and minimum bid price requirements. While an extension has been granted until August 13, 2025, contingent on the acquisition of SB Security Holdings, LLC, failure to comply could result in delisting.

Regulatory & Compliance Risks:

• Ongoing Regulatory Scrutiny: Approved products remain subject to extensive ongoing regulatory requirements for manufacturing, labeling, promotion, and post-marketing surveillance. Failure to comply could result in significant regulatory actions, including withdrawal of approval or criminal penalties.
• Healthcare Laws and Regulations: Business activities are subject to federal and state healthcare fraud and abuse laws (e.g., Anti-Kickback Statute, False Claims Act, Physician Payments Sunshine Act, HIPAA). Non-compliance could lead to substantial penalties.
• Environmental, Health and Safety: Research, development, and manufacturing activities involve hazardous materials, posing risks of contamination, fines, or operational interruptions if environmental, health, and safety laws are not complied with.

Geopolitical & External Risks

Geopolitical Exposure: Operating internationally exposes the Company to business, regulatory, political, operational, financial, and economic risks associated with doing business in various global jurisdictions, including conflicting laws, difficulties in managing foreign operations, and financial risks.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Gene Therapy (α-Klotho gene): The Company's primary focus is on a proprietary, patented gene therapy platform utilizing the α-Klotho gene and its secreted isoform (s-KL) to treat neurodegenerative diseases and other age-related pathologies. This includes product candidates KLTO-101 for Alzheimer's disease and KLTO-202 for ALS. The Company is investing in this area through exclusive licenses and a Sponsored Research Agreement with Universitat Autònoma de Barcelona.
• Biosimilar Biologics: Development of off-patent bio generic antibodies for cancer and autoimmune diseases, including rituximab, trastuzumab, bevacizumab, and cetuximab.
• Generic Drugs: Portfolio of five market-approved anti-cancer drugs for metastatic colorectal, gastric, and lung cancers.

Innovation Pipeline:

• KLTO-202 (ALS): Pre-clinical development is underway, with plans to complete animal toxicology and submit an IND application to the FDA in 2025 for a Phase I "Compassionate Use" study in late-stage ALS patients.
• KLTO-101 (Alzheimer’s): Pre-clinical development is scheduled to follow KLTO-202 by six to nine months, with plans to seek a corporate partner for this indication.
• Diagnostic Assay Development: Developing and validating a new assay method in 2025 to separate and individually measure all Klotho protein isoforms (s-KL, m-KL, p-KL) and metabolites (KL1, KL2), which could potentially become a clinical biomarker.
• Delivery Technologies: Building a platform of next-generation gene and cell delivery technologies, including AAV-based, Lentivirus-based, and lipid-based gene therapies, to optimize safety, potency, durability, and clinical response.

Intellectual Property Portfolio:

• Patent Strategy: The Company relies on a combination of licensed patents and trade secret protection. Key licenses include:
  • Exclusive, worldwide rights from Universitat Autònoma de Barcelona (UAB) and Institució Catalana De Recerca I Estudis Avançats (ICREA) for s-KL gene therapy for neurodegenerative diseases, with patents issued in the U.S. (No. 12,036,268), Europe, China, and Hong Kong, enforceable until November 21, 2036.
  • Exclusive, worldwide rights from UAB/ICREA/CIBER/VHIR for Neuronal or Neuromuscular Diseases, with pending patent applications (US 18/299,989, PCT/EP2023/059677), potentially enforceable until April 16, 2043 if granted.
  • Non-exclusive, worldwide license from University of Heidelberg, Germany, for modified AAV capsid polypeptides for neuromuscular disorders, with pending patent applications potentially enforceable until April 26, 2039 if granted.
• Licensing Programs: The Company has entered into various exclusive and non-exclusive license agreements covering its key technologies, including those with Reliance Life Sciences for biosimilars and TransferTech Sherbooke for a needleless syringe technology.

Technology Partnerships:

• Universitat Autònoma de Barcelona (UAB) and Institució Catalana De Recerca I Estudis Avançats (ICREA).
• Consorcio Centro de Investigación Biomédica en Red (CIBER) and Fundació Hospital Universitari Vall D’hebron — Institut de Recerca (VHIR).
• University of Heidelberg, Germany.
• Reliance Life Sciences Private Limited (RLS).

Leadership & Governance

Executive Leadership Team

Leadership Continuity: Not explicitly discussed in the filing.

Board Composition: The Board of Directors consists of five members, including the Chief Executive Officer. Directors serve a single class with terms ending at the next annual stockholder meeting.

• Audit Committee: Samuel Zentman (Chairperson), Jon McGarity, and Riad El-Dada. All members are independent and financially literate, with Samuel Zentman qualifying as an "audit committee financial expert."
• Compensation Committee: Jon McGarity (Chairperson), Samuel Zentman, and Shalom Hirschman. All members are independent.
• Nominating and Corporate Governance Committee: Shalom Hirschman (Chairperson), Jon McGarity, and Samuel Zentman. All members are independent.
• Scientific Advisory Board (SAB): Comprises distinguished experts in neurodegenerative diseases (Robert Langer, Sc.D., Makoto Kuro-o, M.D., Ph.D., Merit Cudkowicz, M.D., M.Sc.) and longevity (D. Craig Willcox, MHSc, Ph.D., FGSA, Michio Shimabukuro, M.D., Ph.D., Bradley J. Willcox M.D., M.Sc., FGSA, FRSM, Richard Allsopp, Ph.D.).

Human Capital Strategy

Workforce Composition:

• Total Employees: As of January 24, 2025, the Company has three full-time employees.
• Geographic Distribution: Not explicitly detailed, but employees provide rent-free remote offices in Omaha, NE, Charlotte, NC, and Scottsdale, AZ.
• Skill Mix: The Company utilizes the services of four consultants in addition to its full-time employees.

Talent Management: Acquisition & Retention: The Company acknowledges the intense competition for qualified personnel in the biotechnology and pharmaceutical industries. It believes that equity awards with time-based vesting features promote executive retention.

• Employee Value Proposition: Equity awards are used to link executive officers' interests with long-term Company performance and create an ownership culture.

Diversity & Development: No specific information on diversity metrics or formal development programs was disclosed in the filing.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• Pharmaceutical and Biological Products: All product candidates are subject to extensive regulation by governmental authorities in the U.S. (FDA), Europe (EMA), Japan, and other countries. This includes rigorous pre-clinical testing, clinical trials, manufacturing (cGMP), labeling, packaging, storage, distribution, and post-approval monitoring.
• Gene Therapy Products: Subject to specific and frequently changing regulatory requirements. The FDA's Office of Tissues and Advanced Therapies (CBER) and the Cellular, Tissue and Gene Therapies Advisory Committee oversee these products.
• Biosimilar Products: Approval pathway established by the Biologics Price Competition and Innovation Act of 2009 (BPCIA) in the U.S. and a similar pathway in the EU since 2003. Requires demonstration of biochemical and biologic biosimilarity to a reference product.
• International Compliance: Approval processes vary by country, often requiring additional data or studies beyond U.S. approval.

Trade & Export Controls: Not explicitly detailed beyond general international business risks.

Legal Proceedings: The Company reported no material legal proceedings.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: The Company's expected income tax due (recovery) is calculated at a statutory tax rate of 21%.
• Net Operating Losses (NOLs): As of December 31, 2024, the Company had federal and state net operating loss carryforwards of approximately $2,390,000 and $1,099,000, respectively, which do not expire. A full valuation allowance has been provided against its net deferred tax assets due to no history of generating taxable income.
• Tax Reform Impact: The 2017 Act reduced the corporate tax rate to 21% and limits the utilization of NOL carryforwards arising after December 31, 2017, to 80% of taxable income, with indefinite carryforward.
• Geographic Tax Planning: The Company is subject to franchise tax filing requirements in the State of Delaware.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: The Company carries Directors and Officers' liability insurance.
• Risk Transfer Mechanisms: The Company does not currently carry biological or hazardous waste insurance coverage, which is noted as a risk.